Русский
Lorlatinib in the treatment of ALK-positive non-small cell lung cancer
DOI: https://dx.doi.org/10.18565/pharmateca.2023.6-7.48-53
O.O. Gordeeva, N.A. Meshcheryakova, A.A. Meshcheryakov
1) Lopukhin Federal Research and Clinical Center of Physical and Chemical Medicine of Federal Medical and Biological Agency, Moscow, Russia; 2) National Medical Research Center of Oncology. N.N. Blokhin, Moscow, Russia
Due to the advent of targeted drugs in the treatment of ALK-positive non-small cell lung cancer, it has now become possible to prescribe treatment that is more effective and less toxic than chemotherapy. This review focuses on the latest approved third-generation ALK inhibitor, lorlatinib. The data of clinical studies, confirming the effectiveness of the drug both in the first and subsequent lines of therapy, as well as the place of the drug in accordance with currently accepted clinical guidelines are presented. A clinical observation demonstrating the effectiveness of the drug in a patient with ALK-positive non-small cell lung cancer in the second line of therapy is discussed.
About the Autors
Corresponding author: Olga O. Gordeeva, Cand. Sci. (Med.), Oncologist, Chemotherapist, Lopukhin Federal Research and Clinical Center of Physical and Chemical Medicine of Federal Medical and Biological Agency, Moscow, Russia; gordeeva.o@rcpcm.org
Similar Articles
